Several other drugs, including novel oxime derivatives of radicicol (71) and novobiocin (72), have been shown to be effective for the therapeutic intervention of CML by disrupting the Bcr–Abl–Hsp90 complex. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.